|
Follow-up data |
|||
| Subcutaneous group (n = 115) |
Intramuscular group (n = 92) |
95% confidence interval of the difference |
|
|
|
|||
| Mean circumference of the arm (SD), cm, 24 h |
32,1 (3,4) |
32,2 (4,2) |
|
| Mean change circumference of the arm (SD), cm, 24 h |
+0,20 (1,44) |
+0,28 (0,91) |
-0,40 to +0,25 * |
| Patients with increase of the circumference of the arm >= 1 cm, n (%), 24 h |
27 (23,5%) |
18 (19,6%) |
-7,3% to +15,1% |
| Patients with skin lesions in the administration area, n (%), 24 h |
43 (37,4%) |
16 (17,4%) |
+8,2% to +31,8% |
| Erythema, n |
36 |
8 |
|
| Papule, n |
0 |
3 |
|
| Plaque, n |
7 |
5 |
|
| Nodule, n |
0 |
2 |
|
| Cyst, n |
0 |
0 |
|
| Vesicle, n |
0 |
0 |
|
| Blister, n |
0 |
0 |
|
| Ulcer, n |
0 |
0 |
|
| Scab, n |
0 |
2 |
|
| Haematoma, n |
2 |
1 |
|
| Pruritus, n |
4 |
2 |
|
| Insensitivity, n |
1 |
0 |
|
| Mean Visual Analog Pain Scale (SD), 24 h |
0,43 (1,08) |
0,29 (0,84) |
-0,12 to 0,41 * |
| Patients with Visual Analog Pain Scale > 0, n (%), 24 h |
23 (20,0%) |
13 (14,1%) |
-4,3% to +16,1% |
| Mean INR (SD), 24 h |
2,28 (0,64) |
2,30 (0,70) |
|
| Mean change INR (SD), 24 h |
+0,04 (0,50) |
-0,06 (0,55) |
-0,04 to +0,25 * |
| Mean INR (SD), 10d |
2,31 (0,67) |
2,44 (0,95) |
|
| Mean change INR (SD), 10d |
+0,08 (0,79) |
+0,07 (0,93) |
-0,24 to +0,24 * |
|
*Calculated under the checked assumption of variance homogeneity of both samples. | |||
Casajuana et al. BMC Blood Disorders 2008 8:1 doi:10.1186/1471-2326-8-1 |
|||